SCHEMBL23973233

SCHEMBL23973233

O=c1[nH]c(C2(c3ccc(Cl)cc3)CC2)nc2c1CNCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 4/20 0.39
WNT3A P56704 1/20 0.39
TNKS O95271 3/20 0.38
MAPT P10636 1/20 0.37
HTR2C P28335 3/20 0.36
HTR2B P41595 2/20 0.36
HTR2A P28223 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
MMP13 P45452 1/20 0.36
SOS1 Q07889 1/20 0.35
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
GSK3B P49841 2/20 0.34
CDK5 Q00535 2/20 0.34
CDK5R1 Q15078 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973236 0.88 TNKS2 (0.39) TNKS2WNT3ATNKSHTR2CPARP1
SCHEMBL23973234 0.88 HTR2C (0.41) TNKS2TNKSMAPTHTR2CHTR2B
SCHEMBL23973237 0.88 HTR2C (0.40) TNKS2WNT3ATNKSMAPTHTR2C
SCHEMBL23972481 0.88 HTR2C (0.44) TNKS2TNKSMAPTHTR2CHTR2B
SCHEMBL23973137 0.86 MAPT (0.42) TNKS2WNT3ATNKSMAPTHTR2C
SCHEMBL23972276 0.86 TP53 (0.40) TNKS2TNKSMAPTHTR2CHTR2B
SCHEMBL23973342 0.86 HTR2C (0.42) TNKS2TNKSMAPTHTR2CHTR2B
SCHEMBL23973232 0.85 TNKS2 (0.46) TNKS2WNT3ATNKSHTR2CHTR2B
SCHEMBL23973231 0.85 TNKS (0.36) TNKS2TNKSMAPTHTR2CHTR2B
SCHEMBL30284329 0.85 TNKS (0.36) TNKS2TNKSMAPTHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 TNKS2 1601/4885WNT3A 2816/4885TNKS 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.